Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development wi...
The record date will be 5 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023, and The distribution date will be 11:59 p.m. Burlington, North...
SciTech Development today announced it has closed a $2.73M funding round, led by several prominent life science investors to advance clinical trials for No...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform techn...
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, Texas Enrolment now open to patient...
HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated fro...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were repor...
STP122G is part of the Group's GalAhead™ Factor XI RNAi therapeutic program, which has applications across a broad range of disease indications such ...
"We are excited to announce this partnership with Tabuk Pharmaceuticals, as it represents the next step in bringing the first disease modifying therapy for...
HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in pr...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is an exciting next step in the development of imlifidase and for patients with anti-...
© 2025 Biopharma Boardroom. All Rights Reserved.
